deucravacitinib
Bristol Myers Squibb announces new $2.3bn campus in the US
Texas has been chosen as the site for a new, state-of-the-art multi-modal manufacturing campus
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
The drug showed improvements in overall survival and progression-free survival in two cancers
J&J’s Icotyde approved by US FDA for plaque psoriasis
Plaque psoriasis affects over 125 million people worldwide
Bristol Myers Squibb evolves and expands multiple myeloma programme
Created in 2016, the Standing in the Gaap programme aims to advance more equitable care
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
Bristol Myers Squibb’s Sotyktu approved by US FDA for psoriatic arthritis
Sotyktu is the first TYK2 inhibitor approved for active psoriatic arthritis
Takeda’s zasocitinib demonstrates positive results in plaque psoriasis
Around 64 million people worldwide live with psoriasis
BMS announces affordable drug price agreement with US government
The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid
BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation
The report shows how prehabilitation can improve patient experience while alleviating capacity pressures
BMS acquires Orbital Therapeutics in $1.5bn deal
The deal includes several next-gen cell therapy candidates for autoimmune diseases